Date: 2013-09-30
Type of information: R&D agreement
Compound: biologic immunomodulatory product
Company: UCB (Belgium) Vectura (UK)
Therapeutic area: Inflammatory diseases - Respiratory diseases
Type agreement: R&D
development
Action mechanism:
Disease: severe inflammatory respiratory disease
Details: * On September 30, 2013, UCB and Vectura have announced that they have entered into a collaboration for the development of an innovative biologic immunomodulatory product in the area of severe inflammatory respiratory disease. The collaboration will focus on bringing to clinical proof-of-concept a UCB-generated biological therapy targeting a key molecule in the immune system. The companies will jointly manage the programme, with UCB focusing on bioprocess and preclinical development and Vectura taking responsibility for the pharmaceutical and clinical development of the dry powder product through to clinical proof-of-concept.
Financial terms: Financial terms of the collaboration have not been disclosed.
Latest news: * On June 4, 2015, Vectura announced that, following the successful completion of a number of pre-clinical studies, enrolment has commenced into a Phase I clinical study (VR942-1-001) in healthy volunteers and patients with asthma.
